• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Topcon developer recognized for biomedical optics contribution

Article

Topcon Medical Laser Systems announced that Daniel Palanker, PhD, has received the International Society for Optics and Photonics’ 2014 Translational Research Award.

 

Santa Clara, CA-Topcon Medical Laser Systems announced that Daniel Palanker, PhD, has received the International Society for Optics and Photonics’ 2014 Translational Research Award.

Dr. Palanker-associate professor in the Department of Ophthalmology at Stanford University, Stanford, CA, and key contributor to the development of Topcon’s Endpoint Management-was presented the award for his presentation, “Non-damaging laser therapy of the macula: Titration algorithm and tissue response.”

The presentation highlighted recent findings by Dr. Palanker and colleague, Daniel Lavinsky, MD (Porto Alegre, Brazil) on the efficacy of photo-thermal stimulation of the retina for the treatment of retinal diseases, confirmed in recent clinical trials.

“We’ve developed algorithms that take us, reliably, from the titration settings into the desired treatment range,” Dr. Palanker said. “It provides optimal treatment settings for every patient, resulting in beneficial and reproducible outcomes.”

Greg Fava, senior director of marketing at Topcon, said the company was “very excited” for Dr. Palanker’s recognition and accomplishments.

“The award supports our efforts in offering ophthalmologists and patients the most technologically sophisticated system for treating a variety of debilitating retinal diseases,” Fava said. “The ability to treat sub-visibly, effectively, and with visible landmarks constitutes a significant advancement from previous laser technologies, and we are proud to be able to offer this technology to patients and ophthalmologists worldwide.”

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.